Eight mainland China-based companies – five of them biotech firms – passed listing hearings on the Hong Kong stock market in April, clearing the way for them to tap the city’s deep liquidity. The influx, including an AI-driven drug discovery firm, a driverless technology developer and a maker of industrial robots, comes as the China Securities Regulatory Commission (CSRC) has been pushing private firms to list in Hong Kong.